SCHEMBL503512

SCHEMBL503512

CCN(c1ccccc1)c1ccc(-n2c(CC(=O)O)c(C(=O)O)c3cc(Oc4ccc(OC(F)(F)F)cc4)ccc32)cc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PPARG P37231 4/20 0.43
PPARA Q07869 2/20 0.43
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
USP14 P54578 1/20 0.38
ELANE P08246 1/20 0.38
MAPT P10636 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
ALDH1A1 P00352 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
THRB P10828 2/20 0.37
TP53 P04637 2/20 0.37
PLA2G4A P47712 1/20 0.36
NPY1R P25929 1/20 0.35
NPY2R P49146 1/20 0.35
CETP P11597 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL503553 0.94 ELANE (0.39) PPARGPPARAKDM4EMEN1KMT2A
SCHEMBL333566 0.91 PPARG (0.41) PPARGPPARAKDM4EMEN1KMT2A
SCHEMBL10076916 0.89 PPARG (0.47) PPARGPPARAKDM4EMEN1KMT2A
SCHEMBL333665 0.89 MEN1 (0.44) PPARGPPARAKDM4EMEN1KMT2A
SCHEMBL333656 0.85 PPARG (0.43) PPARGPPARAKDM4EMEN1KMT2A
SCHEMBL503870 0.84 MRGPRX4 (0.47) PPARGPPARAKDM4EMEN1KMT2A
SCHEMBL504095 0.84 KDM4C (0.38) PPARGPPARAKDM4EMEN1KMT2A
SCHEMBL333774 0.84 PPARG (0.46) PPARGPPARAMEN1KMT2APLA2G4A
SCHEMBL333611 0.84 PPARG (0.47) PPARGPPARAKDM4EMEN1KMT2A
SCHEMBL504356 0.83 PPARG (0.42) PPARGPPARAKDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120029016-A1 Indoles Useful in the Treatment of Inflammation BIOLIPOX AB (SW) 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120029016-A1 Indoles Useful in the Treatment of Inflammation LTC4S, LTB4R2, LTB4R PPARG 3260/4885PPARA 1860/4885KDM4E 1630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.